Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Short term Debt (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 4 years of Short term Debt data on record, last reported at $12.5 million in Q3 2025.

  • For Q3 2025, Short term Debt changed N/A year-over-year to $12.5 million; the TTM value through Sep 2025 reached $12.5 million, changed N/A, while the annual FY2024 figure was $12.9 million, N/A changed from the prior year.
  • Short term Debt reached $12.5 million in Q3 2025 per VRCA's latest filing, down from $12.7 million in the prior quarter.
  • Across five years, Short term Debt topped out at $42.3 million in Q2 2022 and bottomed at $12.5 million in Q3 2025.
  • Average Short term Debt over 4 years is $30.0 million, with a median of $40.8 million recorded in 2021.
  • The widest YoY moves for Short term Debt: up 3.27% in 2022, down 3.14% in 2022.
  • A 4-year view of Short term Debt shows it stood at $41.7 million in 2021, then increased by 1.44% to $42.3 million in 2022, then tumbled by 69.41% to $12.9 million in 2024, then dropped by 3.71% to $12.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Short term Debt were $12.5 million in Q3 2025, $12.7 million in Q2 2025, and $12.8 million in Q1 2025.